Real-world study of cabozantinib treatment of advanced renal cell carcinoma in Taiwan
This Taiwanese study found the real-world effectiveness and tolerability of cabozantinib after previous antiangiogenic therapy to be consistent with the results of the METEOR trial.
Authors
- Jhe‐Cyuan Guo (ORCID: https://orcid.org/0000-0002-6689-9640)
- Jian‐Ri Li (ORCID: https://orcid.org/0000-0002-4626-9369)
- Chuan-Shu Chen
- Yu‐Li Su (ORCID: https://orcid.org/0000-0002-1289-473X)
- Kun‐Yuan Chiu (ORCID: https://orcid.org/0000-0002-1854-7376)
- Irene A. Chang (ORCID: https://orcid.org/0000-0002-8062-3181)
- Chi-Ping Huang
- Po‐Jung Su (ORCID: https://orcid.org/0000-0002-6228-9650)
- Yu-Chieh Tsai
- Valérie Perrot (ORCID: https://orcid.org/0000-0002-5541-728X)
- Yen-Hwa Chang
- Hsiao-Jen Chung (ORCID: https://orcid.org/0000-0003-4865-1251)
- Ching‐Chia Li
Institutions
- Kaohsiung Medical University (TW)
- Ipsen (France) (FR)
- China Medical University (TW)
- Kaohsiung Medical University Chung-Ho Memorial Hospital (TW)
- Taipei Veterans General Hospital (TW)
- Taichung Veterans General Hospital (TW)
- Kaohsiung Chang Gung Memorial Hospital (TW)
- Linkou Chang Gung Memorial Hospital (TW)
- China Medical University Hospital (TW)
- National Taiwan University Hospital (TW)
Publication Details
- Journal
- Journal of the Formosan Medical Association
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1016/j.jfma.2025.03.016
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ipsen